Ethics statement
This trial was approved by the National Health Research and Ethics Committee of the Ministry of Health of Lesotho (118–2019; June 3, 2019) and the ethics committee in Switzerland (Ethikkommission Nordwest- und Zentralschweiz; 2019–00480; June 14, 2019). The trained study staff obtained the individual written informed consent from the participants before inclusion into the PEBRA trial. To minimize selection bias, the ethics committees agreed to waive parental consent for the 15 to 17 years old study participants as outlined in the approved PEBRA study protocol [